Novel therapies for peripheral T-cell lymphomas
نویسندگان
چکیده
منابع مشابه
Peripheral T-cell lymphomas.
The development of T cells from stem (progenitor) cells to effector cells results from a two-wave process of proliferation and differentiation. The cells of the first differentiation wave are the precursor T cells, and those of the second differentiation wave are peripheral T cells. In the first differentiation wave, resting/circulating naive antigen-reactive T lymphocytes are produced which di...
متن کاملNovel therapies and role of transplant in the treatment of peripheral T-cell lymphomas.
Peripheral T-cell lymphomas (PTCL) are an uncommon, heterogeneous group of non-Hodgkin lymphomas that carry a much poorer prognosis than their more common B-cell counterparts. The most commonly used treatment is CHOP or its variations. However, while the results with CHOP are inadequate, there is little compelling data to suggest a preferred alternate strategy. Many of these alternate strategie...
متن کاملImmunophenotyping of Nodal Peripheral T-cell Lymphomas and its Association with Epstein-Barr Virus
Background: Immunophenotyping in the rare group of nodal Peripheral T-cell Lymphomas (PTCL) exposes interesting features such as T-cell marker downregulation and paradoxically, the presence of reactive, clustered large-sized CD20 positive B-cells (B-cell proliferation). Epstein-Barr virus (EBV) has been suggested as a putative etiology in pathogenesis of B-cell lymphoma. We aimed to review the ...
متن کاملPathobiology of peripheral T-cell lymphomas.
Peripheral T-cell lymphomas (PTLs) are uncommon, accounting for fewer than 10% of all non-Hodgkin lymphomas. Success in therapy of the PTLs has lagged behind that of aggressive B-cell lymphomas, and most PTLs have a poor prognosis. The molecular pathogenesis of most PTLs is also poorly understood. In the WHO classification, clinical features, in conjunction with morphological and immunophenotyp...
متن کاملPeripheral t-cell lymphomas: progress and challenges
Peripheral T-cell lymphomas (PTCLs) represent a complex group of diseases that remain a management challenge today. Although CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) is considered the standard therapy, outcomes are disappointing and relapses are frequent. Therapeutic progress has lagged behind that for the more common and aggressive B-cell lymphomas. With disease rarity,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Therapeutic Advances in Hematology
سال: 2013
ISSN: 2040-6207,2040-6215
DOI: 10.1177/2040620713481980